Studies on congenital orotic aciduria: comparison of orotic acid metabolism in microorganisms.

L. Smith,M. Lotz

1963-02-01

Journal of Laboratory and Clinical Medicine

Abstract:

What problem does this paper attempt to address?

Growth differentiation factor–15 predicts the prognoses of patients with acute coronary syndrome: a meta-analysis

Shangshi Zhang,Dongjun Dai,Xian Wang,Hongyan Zhu,Hongchuan Jin,Ruochi Zhao,Liting Jiang,Qi Lu,Fengying Yi,Xiangxiang Wan,Hanbin Cui

DOI: https://doi.org/10.1186/s12872-016-0250-2

IF: 2.174

2016-01-01

BMC Cardiovascular Disorders

Abstract:Background Recent studies have shown Growth differentiation factor–15 (GDF-15) that is a member of the transforming growth factor β (TGF-β) superfamily might be a potential predictive cytokine for the prognosis of Acute coronary syndrome (ACS). However, there are discrepancies in these studies. Methods Publication searches of the PubMed/Medline and EMBASE databases were performed without any time or ethnicity restrictions. The inclusion and exclusion criteria, when clear, were addressed. Random effects models were used for all analyses. Publication bias was tested using funnel plots and the Egger test. Results We identified eight eligible studies that provided mortality data. Five of these studies provided recurrent myocardial infarction (MI) data. The maximal duration of follow-up ranged from 6 months to 6 years. A significant association was found between the patients with the highest and lowest GDF-15 levels (overall analyses) in terms of mortality ( p < 0.00001; RR = 6.08; 95 % CI = 4.79–7.71) and recurrent MI ( p < 0.00001; RR = 1.76; 95 % CI = 1.49–2.07). We also found significant associations between the subgroup analyses stratified by ACS types, cutoff points and follow-up durations ( p < 0.001). The combined hazard ratio was high for GDF-15 to ACS (HR = 1.656, 95 % CI = 1.467–1.871). Conclusion High plasma GDF-15 levels are associated with an increased risk of mortality and recurrent MI in patients with ACS.
Monochromatic light sources in testing image intensifier tubes

K. Chrzanowski,omiej Radzik

Abstract:Military standards and literature sources recommend use of polychromatic light source of 2856K color temperature in testing image intensifier tubes. Tungsten halogen bulbs are standard sources of radiation used in commercially available test stations. However, there are two main disadvantages of tungsten bulbs: short life time and temporal changes of both light power and light spectrum. Application of monochromatic semiconductor sources in testing of image intensifiers as possible alternative of halogen bulbs is analyzed in this paper. It is shown that, if calibrated properly, monochromatic semiconductor sources can be used in stations for testing image intensifier tubes. Military standards require use of polychromatic light sources of 2856K color temperature in testing image intensifier tubes[1.a.i.[1]-1.a.i.[6]]. Tungsten halogen bulbs have been standard sources of radiation used in commercially available test stations for last few decades in testing image intensifier tubes [1.a.i.[7],1.a.i.[8]]. However, tungsten halogen bulbs have several significant limitations. First, they are not stable and emitted flux varies significantly in time. Second, they are characterized by short life time. Third, due to significant temporal inertia it is necessary to use mechanical shutters to enable tests of temporal characteristics of image intensifier tubes (II tubes). Sensitivity of image intensifier tubes depends significantly on wavelength. Therefore, illumination of the photocathode with 2856K color temperature light is not equivalent to illumination with monochromatic light of the same radiation power. However, let us analyze if properly calibrated monochromatic sources can replace 2856K color temperature halogen bulbs in test equipment to be used for testing image intensifier tubes and if accurate measurement of photometric parameters of II tubes is still possible. Quantitative relationships between input illuminance and output luminance is measured during the photometric tests of II tubes. The MIL standards state very precisely the necessary illuminance levels of 2856K color radiation to be used during measurement of photometric parameters of II tubes. The conversion coefficient between the illuminance level of 2856K light and the equivalent illuminance level of monochromatic light depends on spectral sensitivity curve of the tested tube that can vary with different tubes. Therefore we should use different conversion coefficients in order to calibrate properly the monochromatic source used during tests of tubes of different spectral sensitivity. * E-mail: kch@inframet.pl This feature is a significant drawback of semiconductor light sources but still in case of testing large number of II tubes of the same spectral sensitivity such monochromatic sources should be an interesting alternative of typical halogen bulbs. Here we will analyze possible application of monochromatic semiconductor sources (LED diodes) in testing of image intensifier tubes. These monochromatic sources are much more stable, are characterized by negligible temporal inertia and do not cause polychromatic aberration. Such sources are used sometimes in commercially available stations for testing II tubes [1.a.i.[7],1.a.i.[8]]. However, so far their applications have been limited to use in measurements of imaging parameters (resolution, MTF, image quality etc) of II tubes when, according to MIL standards, requirements on accuracy of illumination level are low. Here we are to investigate if it is possible to use semiconductor light sources in testing photometric parameters of II tubes (luminous sensitivity, luminance gain, etc) when requirements on accuracy of illumination level are high. In order to calibrate properly monochromatic source to be used instead of standard polychromatic light sources we will need an instrument that is sensitive to both polychromatic and monochromatic light. Let us make an assumption that we will use typical illuminance meters of spectral characteristics identical as spectral characteristics of humans eye as the sensing instrument of both polychromatic and monochromatic illumination at tube photocathode plane. The illuminace meters of sensitivity over 1 mlx are relatively low cost meters available at photometric laboratories. Next, let as assume that we will use a monochromatic source emitting light in the spectral range where both the tested II tubes and the illuminance meters are sensitive: from about 0.5 μm to 0.65μm. Krzysztof Chrzanowski, *1,2 Tomasz Raźniewski, Bartłomiej Radzik Military University of Technology, 2 Kaliski str., 00-908 Warsaw, Poland, Inframet, Graniczna 24, Kwirynow, 05-082 Stare Babice, Poland Received April 28, 2009; accepted June 29, 2009; published June 30, 2009 http://www.photonics.pl/PLP © 2009 Photonics Society of Poland PHOTONICS LETTERS OF POLAND, VOL. 1 (2), 79-81 (2009) 80 Now, let us analyse a situation when the photocathode of the image intensifier tube was illuminated using polychromatic 2856 K light and the illuminance meter recorded illuminance level Ep, and when the photocathode of the image intensifier tube was illuminated using monochromatic light the illuminance meter recorded illuminance level Em. Let us find what is the relationship between Ep and Em necessary to achieve situation when both light sources generate the same luminance level at the screen of the illuminated II tube. The light coming to the photocathode represent a certain stimulus that is measured by the illuminance meter in photometric units perfectly suitable for humans eye. Here however, let us analyse a case when the receptor of this stimulus is not human eye but image intensifier tube of significantly different spectral curve. If we use a light meter of spectral curve identical as tube curve then the corrected indication of the illuminace meter illuminated using polychromatic light Ep(cor) would be
Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease

Emil Hagström,Claes Held,Ralph A H Stewart,Philip E Aylward,Andrzej Budaj,Christopher P Cannon,Wolfgang Koenig,Sue Krug-Gourley,Emile R Mohler 3rd,Philippe Gabriel Steg,Elizabeth Tarka,Ollie Östlund,Harvey D White,Agneta Siegbahn,Lars Wallentin,STABILITY Investigators

DOI: https://doi.org/10.1373/clinchem.2016.260570

Abstract:Background: Higher growth differentiation factor 15 (GDF-15) concentrations are associated with cardiovascular (CV) and non-CV morbidity and mortality. However, information on associations between GDF-15 and the risk of specific CV and non-CV events in stable coronary heart disease (CHD) patients is limited. Methods: In 14 577 patients with stable CHD participating in the Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial (STABILITY), GDF-15 and other prognostic biomarkers (N-terminal pro-B-type natriuretic peptide, high-sensitivity troponin T, cystatin C, and high-sensitivity C-reactive protein) were measured. In adjusted Cox regression models, the associations between GDF-15 and the composite CV end point [CV death, myocardial infarction (MI), and stroke], as well as other CV and non-CV events, were assessed. Results: The median concentration (interquartile range) of GDF-15 at baseline was 1253 (915-1827) ng/L. The hazard ratio for the composite end point for the highest compared to the lowest quartile of GDF-15 was 1.8 (95% CI, 1.5-2.2); for CV death, 2.63 (1.9-3.6); for sudden death, 3.06 (1.9-4.8); for heart failure (HF) death, 4.3 (1.3-14); for cancer death, 2.5 (1.3-4.7); for hospitalization for HF, 5.8 (3.2-10); for MI 1.4 (95% CI, 1.1-1.9); and for stroke, 1.8 (95% CI, 1.1-2.8). After adjustment for other prognostic biomarkers, GDF-15 remained significantly associated with all outcomes except for MI. Conclusions: In stable CHD, GDF-15 was independently associated with CV, non-CV, and cancer mortality, as well as with MI and stroke. When also adjusting for other prognostic biomarkers, the associations to all fatal and nonfatal events were maintained except for MI. Information on GDF-15, therefore, might be helpful when assessing the risk of adverse outcomes in patients with stable CHD. ClinicalTrials.gov Identifier: NCT00799903.
Growth Differentiation Factor 15: A Prognostic Marker in Patients with Acute Chest Pain without Acute Myocardial Infarction

Gard M S Myrmel,Ole-Thomas Steiro,Hilde L Tjora,Jørund Langørgen,Rune Bjørneklett,Øyvind Skadberg,Vernon V S Bonarjee,Øistein R Mjelva,Eva K R Pedersen,Kjell Vikenes,Torbjørn Omland,Kristin M Aakre

DOI: https://doi.org/10.1093/clinchem/hvad015

2023-06-01

Abstract:Background: Acute chest pain is associated with an increased risk of death and cardiovascular events even when acute myocardial infarction (AMI) has been excluded. Growth differentiation factor-15 (GDF-15) is a strong prognostic marker in patients with acute chest pain and AMI, but the prognostic value in patients without AMI is uncertain. This study sought to investigate the ability of GDF-15 to predict long-term prognosis in patients presenting with acute chest pain without AMI. Methods: In total, 1320 patients admitted with acute chest pain without AMI were followed for a median of 1523 days (range: 4 to 2208 days). The primary end point was all-cause mortality. Secondary end points included cardiovascular (CV) death, future AMI, heart failure hospitalization, and new-onset atrial fibrillation (AF). Results: Higher concentrations of GDF-15 were associated with increased risk of death from all causes (median concentration in non-survivors vs survivors: 2124 pg/mL vs 852 pg/mL, P < 0.001), and all secondary end points. By multivariable Cox regression, GDF-15 concentration ≥4th quartile (compared to <4th quartile) remained an independent predictor of all-cause death (adjusted hazard ratio (HR): 2.75; 95% CI, 1.69-4.45, P < 0.001), CV death (adjusted HR: 3.74; 95% CI, 1.31-10.63, P = 0.013), and heart failure hospitalization (adjusted HR: 2.60; 95% CI, 1.11-6.06, P = 0.027). Adding GDF-15 to a model consisting of established risk factors and high-sensitivity cardiac troponin T (hs-cTnT) led to a significant increase in C-statistics for prediction of all-cause mortality. Conclusions: Higher concentrations of GDF-15 were associated with increased risk of mortality from all causes and risk of future CV events.
Prognostic value of growth differentiation factor-15 3 months after an acute chest pain admission

Gard Mikael Sæle Myrmel,Ole-Thomas Steiro,Hilde Lunde Tjora,Jørund Langørgen,Rune Oskar Bjørneklett,Øyvind Skadberg,Vernon Vijay Singha Bonarjee,Øistein Rønneberg Mjelva,Eva Ringdal Pedersen,Kjell Vikenes,Torbjorn Omland,Kristin Moberg Aakre

DOI: https://doi.org/10.1136/heartjnl-2023-323260

IF: 5.7

2024-03-12

Heart

Abstract:Objective: Growth differentiation factor-15 (GDF-15) is a predictor of death and cardiovascular events when measured during index hospitalisation in patients with acute chest pain. This study investigated the prognostic utility of measuring GDF-15 3 months after an admission with suspected non-ST-elevation acute coronary syndrome (NSTE-ACS). Methods: GDF-15 was measured at baseline and 3 months after admission in 758 patients admitted with suspected NSTE-ACS. Patients were followed for a median of 1540 (IQR: 1087-1776) days after the 3-month visit. The primary endpoint was all-cause mortality, while the secondary composite endpoint included all-cause mortality, incident myocardial infarction and heart failure hospitalisation during follow-up. Results: In patients with GDF-15 ≥1200 pg/mL (n=248), 18% died and 25% met the composite endpoint. In patients with GDF-15 <1200 pg/mL (n=510), 1.7% died and 4% met the composite endpoint. The GDF-15 concentration (log2 transformed) at 3 months was significantly associated with all-cause mortality (adjusted HR: 2.2, 95% CI: 1.4 to 3.3, p<0.001) and the composite endpoint (adjusted HR: 1.9, 95% CI: 1.4 to 2.7, p<0.001), independently of traditional risk factors and baseline troponin T. A 10% change in GDF-15 concentration from baseline to the 3-month visit was associated with increased risk of all-cause mortality (HR: 1.06, 95% CI: 1.01 to 1.13, p=0.031), adjusting for baseline GDF-15 concentrations. Conclusions: High GDF-15 concentrations 3 months after admission for suspected NSTE-ACS are associated with long-term mortality and cardiovascular events, independent of traditional risk factors and troponin T. A change in GDF-15 concentration can provide prognostic information.
Growth Differentiation Factor 15, Its 12-Month Relative Change, and Risk of Cardiovascular Events and Total Mortality in Patients with Stable Coronary Heart Disease: 10-Year Follow-up of the KAROLA Study

Dhayana Dallmeier,Hermann Brenner,Ute Mons,Wolfgang Rottbauer,Wolfgang Koenig,Dietrich Rothenbacher

DOI: https://doi.org/10.1373/clinchem.2016.254755

Abstract:Background: This study considered whether baseline concentrations and 12-month changes of growth differentiation factor 15 (GDF-15) are associated with subsequent cardiovascular events (CVEs) and total mortality in patients with stable coronary heart disease. Methods: Baseline GDF-15 serum concentrations were measured in 1073 participants in a cardiac rehabilitation program (median follow-up 10 years). GDF-15 associations with subsequent CVE and total mortality were evaluated by Cox-proportional hazards models adjusting for well-established cardiovascular risk factors (Model 2), plus N-terminal probrain natriuretic peptide, high-sensitivity (hs) CRP, and hs cardiac troponin T (Model 3). Results: In our study population [84.7% men, mean age 59 years, median baseline GDF-15 1232 ng/L (interquartile range, 916, 1674)] we observed 190 CVE and 162 deaths. Compared to participants with GDF-15 <1200 ng/L, increased risk for death was found in participants with GDF-15 ≥1200 and ≤1800 ng/L [hazard ratio (HR) 1.68 (95% CI, 1.08-2.62)] and with GDF-15 >1800 ng/L [HR 1.73 (1.02-2.94)], even in Model 3. The 12-month relative median change was -16.7%. As compared to participants with 12-month relative changes between -20% and 20%, GDF-15 increments >20% were associated with: a) an HR of 1.84 (1.04-3.26) for CVE in Model 2, but found nonsignificant in Model 3; (b) an HR of 2.26 (1.32-3.86) for death even in Model 3. Conclusions: GDF-15 at baseline is independently associated with subsequent CVE and 10-year total mortality. Twelve-month relative changes remained associated with subsequent CVE when adjusting for well-established cardiovascular risk factors, and with total mortality even after further adjustment for established cardiac biomarkers.
Growth differentiation factor-15 and 5-years cardiovascular risk in chest pain patients presenting to the emergency department: a multicenter cohort study

L Crisanti,P Lopez-Ayala,J Boeddinghaus,L Koechlin,T Nestelberger,P Bima,J Glaeser,C Spagnuolo,O Miro,F J Martin Sanchez,M Christ,C Mueller

DOI: https://doi.org/10.1093/eurheartj/ehae666.1579

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Background Growth differentiation factor 15 (GDF-15) has been explored as a prognostic biomarker in multiple disease entities, including ischemic heart disease and heart failure (HF), but its role as a prognostic marker in chest pain patients presenting to the emergency department (ED) is unknown. Purpose To investigate the association between GDF-15 and 5-year all-cause mortality, cardiovascular mortality, and major adverse cardiac events (MACE), and to evaluate its prognostic incremental value. Methods Patients presenting to the ED with acute chest pain were prospectively enrolled in an international multicenter diagnostic study. GDF-15 concentrations were measured in a blinded fashion upon ED presentation. Follow-ups were performed at 3 months, 1-, 2- and 5-years. MACE was defined as the composite of cardiovascular mortality, acute myocardial infarction, stroke, and HF rehospitalization. Associations between GDF-15 and each prognostic outcome were modeled using multivariable Cox proportional hazard regression fitting restricted cubic splines to continuous variables. The magnitude of the effect of each GDF-15 unit change on multivariable-adjusted models was assessed graphically using dose-response plots. To compute an HR for the dose-response plots we chose a GDF-15 value of 1200 pg/mL as a reference value as this has been chosen in previous literature1. For the restricted cubic splines three knots were used. The added prognostic value of GDF-15 was evaluated by the increase in the C-statistic between a base and an extended model and the fraction of new information (FNI) provided by GDF-15. Results A total of 4779 chest pain patients had baseline GDF-15 values available. The median age was 61 [48-74] and 33% were female. Higher GDF-15 levels were more strongly associated with heart failure, kidney dysfunction, older age, hypertension, diabetes and coronary artery disease. GDF-15 was independently associated with 5-years all-cause mortality, cardiovascular mortality and MACE (Figure). When adding GDF-15 to a rich-for-prior-information base model which included age, sex, cardiovascular risk factors, creatinine, cardiac troponin and NT-proBNP, GDF-15 provided relevant incremental prognostic discrimination for 5-years all-cause death and cardiovascular death. (Table). Conclusions In chest pain patients presenting to the emergency department, GDF-15 concentration on admission was associated with 5-years all-cause mortality, cardiovascular mortality, and MACE. In addition, it provided relevant incremental prognostic information when added on top of troponin and NT-proBNP, the two current prognostic gold standard biomarkers.FigureTable

cardiac & cardiovascular systems
Association between growth differentiation factor-15 and adverse outcomes among patients with heart failure: A systematic literature review

Ali Javaheri,Mualla Ozcan,Lauren Moubarak,Karen E Smoyer,Michelle I Rossulek,James H Revkin,John D Groarke,Lisa C Tarasenko,Mikhail N Kosiborod

DOI: https://doi.org/10.1016/j.heliyon.2024.e35916

IF: 3.776

2024-08-08

Heliyon

Abstract:Growth differentiation factor-15 (GDF-15) is an emerging biomarker in several conditions. This SLR, conducted following PRISMA guidelines, examined the association between GDF-15 concentration and range of adverse outcomes in patients with heart failure (HF). Publications were identified from Embase® and Medline® bibliographic databases between January 1, 2014, and August 23, 2022 (congress abstracts: January 1, 2020, to August 23, 2022). Sixty-three publications met the eligibility criteria (55 manuscripts and 8 abstracts; 45 observational studies and 18 post hoc analyses of randomized controlled trials [RCTs]). Of the 19 outcomes identified, the most frequently reported longitudinal outcomes were mortality (n = 32 studies; all-cause [n = 27] or cardiovascular-related [n = 6]), composite outcomes (n = 28; most commonly mortality ± hospitalization/rehospitalization [n = 19]), and hospitalization/re-hospitalization (n = 11). The most common cross-sectional outcome was renal function (n = 22). Among longitudinal studies assessing independent relationships with outcomes using multivariate analyses (MVA), a significant increase in risk associated with higher baseline GDF-15 concentration was found in 22/24 (92 %) studies assessing all-cause mortality, 4/5 (80 %) assessing cardiovascular-related mortality, 13/19 (68 %) assessing composite outcomes, and 4/8 (50 %) assessing hospitalization/rehospitalization. All (7/7; 100 %) of the cross-sectional studies assessing the relationship with renal function by MVA, and 3/4 (75 %) assessing exercise capacity, found poorer outcomes associated with higher baseline GDF-15 concentrations. This SLR suggests GDF-15 is an independent predictor of mortality and other adverse but nonfatal outcomes in patients with HF. A better understanding of the prognostic role of GDF-15 in HF could improve clinical risk prediction models and potentially help optimize treatment regimens.
[The role of growth differentiation factor-15 in assessing the prognosis of patients after uncomplicated myocardial infarction]

A S Galyavich,A A Sabirzyanova,L V Baleeva,Z M Galeeva

DOI: https://doi.org/10.18087/cardio.2023.2.n2152

2023-02-28

Kardiologiia

Abstract:Aim To study the role of growth differentiation factor 15 (GDF-15) in the long-term prognosis for patients after uncomplicated myocardial infarction (MI).Material and methods This study included 118 MI patients aged <70 years with and without ST-segment elevation on electrocardiogram (ECG). All patients underwent an examination that included ECG, echocardiography, Holter ECG monitoring, routine laboratory tests, and tests for plasma N-terminal pro-brain natriuretic peptide (NT-proBNT) and GDF-15. GDF-15 was measured by ELISA. The dynamics of patients was evaluated by interviews at 1, 3, 6, and 12 months. The endpoints were cardiovascular death and hospitalization for recurrent MI and/or unstable angina. Results Median concentration of GDF-15 in MI patients was 2.07 (1.55; 2.73) ng/ml. No significant dependence was found between GDF-15 concentration and age and gender, MI localization, smoking, body weight index, total cholesterol, and low-density lipoprotein cholesterol. During 12-month follow-up, 22.8 % of patients were hospitalized for unstable angina or recurrent MI. In 89.6 % of all cases of recurrent events, GDF-15 was ≥2.07 ng/ml. For patients with GDF-15 in the upper quartile, the time dependence of recurrent MI was logarithmic. High concentrations of NT-proBNP in MI patients were also associated with increased risk of cardiovascular death and recurrent cardiovascular events [RR, 3.3 (95 % CI, 1.87-5.96), р=0.046].Conclusion A combination of GDF-15 and NT-proBNP at high concentrations significantly reflects an adverse prognosis for patients with uncomplicated MI within 12 months [RR, 5.4 (95 % CI, 3.4-8.5), р=0.004].
Growth differentiation factor-15 predicts all-cause death and major adverse cardiovascular events in patients with coronary heart disease: a prospective cohort study

Lyu Lyu,Cui Xv,Juan Xu,Zhenzhen Liu,Yanru He,Wenjing Zhu,Lin Lin,Qiang Yang,Yun Wei,Jinda Wang,Taoke Huang,Benchuan Hao,Hongbin Liu

DOI: https://doi.org/10.1007/s11239-024-03019-5

Abstract:The prognostic value of growth differentiation factor-15 (GDF-15) in predicting long-term adverse outcomes in coronary heart disease (CHD) patients remains limited. Our study examines the association between GDF-15 and adverse outcomes over an extended period in CHD patients and firstly assesses the incremental prognostic effect of incorporating GDF-15 into the Framingham risk score (FRS)-based model. This single-center prospective cohort study included 3,321 patients with CHD categorized into 2,479 acute coronary syndrome (ACS) (74.6%) and 842 non-ACS (25.4%) groups. The median age was 61.0 years (range: 53.0-70.0), and 917 (27.6%) were females. Mortality and major adverse cardiovascular events (MACEs) included cardiovascular mortality, myocardial infarction (MI), stroke, and heart failure (HF) (inclusive of HF episodes requiring outpatient treatment and/or hospital admission). Cox regression models assessed the associations between GDF-15 and the incidence of all-cause mortality and MACEs. Patients were stratified into three groups based on GDF-15 levels: the first tertile group (< 1,370 ng/L), the second tertile group (1,370-2,556 ng/L), and the third tertile group (> 2,556 ng/L). The C-index, integrated discrimination improvement (IDI), net reclassification improvement (NRI), and decision curve analysis (DCA) were used to assess incremental value. Over a median 9.4-year follow-up, 759 patients (22.9%) died, and 1,291 (38.9%) experienced MACEs. The multivariate Cox model indicated that GDF-15 was significantly associated with all-cause mortality (per ln unit increase, HR = 1.49, 95% CI: 1.36-1.64) and MACEs (per ln unit increase, HR = 1.29, 95% CI: 1.20-1.38). These associations persisted when GDF-15 was analyzed as an ordinal variable (p for trend < 0.05). Subgroup analysis of ACS and non-ACS for the components of MACEs separately showed a significant association between GDF-15 and both cardiovascular mortality and HF, but no association was observed between GDF-15 and MI /stroke in both ACS and non-ACS patients. The addition of GDF-15 to the FRS-based model enhanced the discrimination for both all-cause mortality (∆ C-index = 0.009, 95% CI: 0.005-0.014; IDI = 0.030, 95% CI: 0.015-0.047; continuous NRI = 0.631, 95% CI: 0.569-0.652) and MACEs (∆ C-index = 0.009, 95% CI: 0.006-0.012; IDI = 0.026, 95% CI: 0.009-0.042; continuous NRI = 0.593, 95% CI: 0.478-0.682). DCA suggested that incorporating GDF-15 into the FRS-based model demonstrated higher net benefits compared to FRS-based models alone (All-cause mortality: FRS-based model: area under the curve of DCA (AUDC) = 0.0903, FRS-based model + GDF-15: AUDC = 0.0908; MACEs: FRS-based model: AUDC = 0.1806, FRS-based model + GDF-15: AUDC = 0.1833). GDF-15 significantly associates with the long-term prognosis of all-cause mortality and MACEs in CHD patients and significantly improves the prognostic accuracy of the FRS-based model for both outcomes.
MOBILE LEARNING USING SMS : A MOBILE BUSINESS APPLICATION

K. Petrova

Abstract:Flexible eLearning strongly relies on student access to personal computers both on campus and from outside. Today the predominant mode of eLearning is "online"Web browsing using a personal computer. It is already predicted that in the near future the number of mobile communication devices (such as mobile phones and handheld computers) will exceed the number of personal computers. Mobility and context-aware services can be used successfully in the educational environment and researchers in the area have already reported numerous experiments with different technologies. We propose to experiment with a "blended" approach, which integrates the mobile and online learning environments. The outcomes of the model include the development of learners' decision-making skills and the improvement of their understanding of mobility and location-based services.
Growth differentiation factor-15 combined with N-terminal prohormone of brain natriuretic peptide increase 1-year prognosis prediction value for patients with acute heart failure: a prospective cohort study.

Ji Hao,Iokfai Cheang,Li Zhang,Kai Wang,Hui-Min Wang,Qian-Yun Wu,Yan-Li Zhou,Fang Zhou,Dong-Jie Xu,Hai-Feng Zhang,Wen-Ming Yao,Xin-Li Li

DOI: https://doi.org/10.1097/CM9.0000000000000449

IF: 6.133

2019-01-01

Chinese Medical Journal

Abstract:BACKGROUND:Clinical assessment and treatment guidance for heart failure depends on a variety of biomarkers. The objective of this study was to investigate the prognostic predictive value of growth differentiation factor-15 (GDF-15) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) in assessing hospitalized patients with acute heart failure (AHF). METHODS:In total, 260 patients who were admitted for AHF in the First Affiliated Hospital of Nanjing Medical University were enrolled from April 2012 to May 2016. Medical history and blood samples were collected within 24 h after the admission. The primary endpoint was the all-cause mortality within 1 year. The patients were divided into survival group and death group based on the endpoint. With established mortality risk factors and serum GDF-15 level, receiver-operator characteristic (ROC) analyses were performed. Cox regression analyses were used to further analyze the combination values of NT-proBNP and GDF-15. RESULTS:Baseline GDF-15 and NT-proBNP were significantly higher amongst deceased than those in survivors (P < 0.001). In ROC analyses, area under curve (AUC) for GDF-15 to predict 1-year mortality was 0.707 (95% confidence interval [CI]: 0.648-0.762, P < 0.001), and for NT-proBNP was 0.682 (95% CI: 0.622-0.738, P < 0.001). No statistically significant difference was found between the two markers (P = 0.650). Based on the optimal cut-offs (GDF-15: 4526.0 ng/L; NT-proBNP: 1978.0 ng/L), the combination of GDF-15 and NT-proBNP increased AUC for 1-year mortality prediction (AUC = 0.743, 95% CI: 0.685-0.795, P < 0.001). CONCLUSIONS:GDF-15, as a prognostic marker in patients with AHF, is not inferior to NT-proBNP. Combining the two markers could provide an early recognition of high-risk patients and improve the prediction values of AHF long-term prognosis. CLINICAL TRIAL REGISTRATION:ChiCTR-ONC-12001944, http://www.chictr.org.cn.
Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial

Inder S Anand,Tibor Kempf,Thomas S Rector,Heike Tapken,Tim Allhoff,Franziska Jantzen,Michael Kuskowski,Jay N Cohn,Helmut Drexler,Kai C Wollert

DOI: https://doi.org/10.1161/CIRCULATIONAHA.109.928846

IF: 37.8

2010-10-05

Circulation

Abstract:Background: Growth-differentiation factor-15 (GDF-15) is emerging as a prognostic biomarker in patients with coronary artery disease. Little is known about GDF-15 as a biomarker in patients with heart failure. Methods and results: The circulating concentration of GDF-15 was measured at baseline (n=1734) and at 12 months (n=1517) in patients randomized in the Valsartan Heart Failure Trial (Val-HeFT). GDF-15 levels at baseline ranged from 259 to 25 637 ng/L and were abnormally high (>1200 ng/L) in 85% of patients. Higher levels were associated with features of worse heart failure and biomarkers of neurohormonal activation, inflammation, myocyte injury, and renal dysfunction. Baseline GDF-15 levels (per 100 ng/L) were associated with the risks of mortality (hazard ratio, 1.017; 95% confidence interval, 1.014 to 1.019; P<0.001) and first morbid event (hazard ratio, 1.020; 95% confidence interval, 1.017 to 1.023; P<0.001). In a comprehensive multiple-variable Cox regression model that included clinical prognostic variables, B-type natriuretic peptide, high-sensitivity C-reactive protein, and high-sensitivity troponin T, GDF-15 remained independently associated with mortality (hazard ratio, 1.007; 95% confidence interval, 1.001 to 1.014; P=0.02) but not first morbid event. At 12 months, the GDF-15 levels had increased by a similar amount in the placebo and valsartan groups (P=0.94). Increases in GDF-15 over 12 months were independently associated with the risks of future mortality and first morbid event also after adjustment for clinical prognostic variables, B-type natriuretic peptide, high-sensitivity C-reactive protein, and high-sensitivity troponin T and their changes. Conclusions: GDF-15 reflects information from several pathological pathways and provides independent prognostic information in heart failure. GDF-15 levels increase over time, suggesting that GDF-15 reflects a pathophysiological axis that is not completely addressed by the therapies prescribed in Val-HeFT.
Prognostic value of growth differentiation factor-15 in patients with coronary artery disease: A meta-analysis and systematic review

Song Zhang,Panpan Hao,Jiaxin Li,Qi Zhang,Xiaoying Yin,Jiali Wang,Yuguo Chen

DOI: https://doi.org/10.3389/fcvm.2023.1054187

IF: 3.6

2023-02-11

Frontiers in Cardiovascular Medicine

Abstract:Background and aims: The predictive value of growth differentiation factor-15 (GDF-15) for individual cardiovascular outcomes remained controversial in patients with coronary artery disease (CAD). We aimed to investigate the effects of GDF-15 on all-cause death, cardiovascular death, MI and stroke in CAD patients. Methods: We searched PubMed, EMBASE, Cochrane library and Web of Science till 30 December, 2020. Hazard ratios (HRs) were combined with fixed or random effect meta-analyses. Subgroup analyses were performed in different disease types. Sensitivity analyses were used to evaluate the stability of the results. Publication bias was tested using funnel plots. Results: A total of 10 studies with 49,443 patients were included in this meta-analysis. Patients with the highest GDF-15 concentrations had significantly increased risk of all-cause death (HR 2.24; 95% CI: 1.95–2.57), cardiovascular death (HR 2.00; 95% CI: 1.66–2.42), MI (HR 1.42; 95% CI: 1.21–1.66) after adjusting clinical characteristics and prognostic biomarkers (hs-TnT, cystatin C, hs-CRP, and NT-proBNP) but except for stroke (HR 1.43; 95% CI: 1.01–2.03, p = 0.05). For the outcome of all-cause death and cardiovascular death, subgroup analyses revealed consistent results. Sensitivity analyses showed that the results were stable. Funnel plots showed that there was no publication bias. Conclusion: In CAD patients with elevated GDF-15 levels on admission, there were independently significant risks for all-cause death and cardiovascular death. The highest concentrations of GDF-15 had a lower predictive effect on MI than all-cause death and cardiovascular death. The association of GDF-15 with the outcome of stroke needs to be further studied.

cardiac & cardiovascular systems
[Correlation Between Levels of Serum Growth Differentiation Factor-15 and Acute Coronary Syndrome].

Ling-bing Zheng,Yan-hong Guo,Hai-yi Yu,Lin Mi,Yu-peng Wang,Wei Gao

DOI: https://doi.org/10.3969/j.issn.1671-167x.2011.02.017

2011-01-01

Abstract:OBJECTIVE:To explore the association between the levels of serum growth differentiation factor-15(GDF-15) and acute coronary syndrome(ACS) in patients undergoing coronary angiography(CAG).METHODS:In this prospective study, 120 candidates (30 healthy controls and 90 patients with ACS) admitted to our hospital from March 2006 to April 2008 were included. The patients with ACS were divided into 3 groups: (1)Group AMI-emergency (AMI-E), including 30 patients with acute myocardial infarction (AMI) who underwent CAG within 12 hours of the onset of symptoms. (2) Group AMI 7-14 d, including 30 patients with AMI who underwent CAG within 7-14 days of the onset of symptoms. (3)Group UAP including 30 patients with unstable angina pectoris. The serum level of GDF-15 was determined by ELISA.RESULTS:The level of GDF-15 for group ACS was (649.0 ± 224.21) ng/L, which was significantly higher than that of control group [(537.2 ± 262.9)ng/L,P<0.01]. The level of serum GDF-15 significantly increased in group AMI-E [(801.6 ± 218.4)ng/L] compared with group AMI 7-14 d [(656.2 ± 252.4)ng/L,P=0.042, 95% CI 1.001-1.061], group UAP [(586.9 ± 225.6)ng/L, P=0.001, 95% CI 0.809-0.950] and control group(P<0.05, 95% CI 1.000-1.012) after being adjusted for relevant covariates. The elevated level of GDF-15 was related to biomarkers, such as white blood cells count (WBC, r(2)=0.276, P=0.002), lactate dehyerogenase(LDH, r(2)=0.288, P=0.004), creatine kinase 2(CK-MB, r(2)=0.350, P<0.001) and troponin T(TnT, r(2) =0.344, P=0.001).CONCLUSION:GDF-15 protein expression increases in ACS, and the level of GDF-15 rapidly increases and remains elevated in the early period of acute myocardial infarction. The elevated level of GDF-15 is related to biomarkers, such as WBC, LDH, CK-MB, and TnT. GDF-15 could be a new and independent biomarker in evaluating the patients with cardiovascular disease.
Growth differentiation factor 15 as mortality predictor in heart failure patients with non-reduced ejection fraction

Ana Belen Mendez Fernandez,Andreu Ferrero-Gregori,Alvaro Garcia-Osuna,Sonia Mirabet-Perez,Maria Jose Pirla-Buxo,Juan Cinca-Cuscullola,Jordi Ordonez-Llanos,Eulàlia Roig Minguell

DOI: https://doi.org/10.1002/ehf2.12621

Abstract:Aims: The prognostic value of biomarkers in patients with heart failure (HF) and mid-range (HFmrEF) or preserved ejection fraction (HFpEF) has not been widely addressed. The aim of this study was to assess whether the prognostic value of growth differentiation factor 15 (GDF-15) is superior to that of N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with HFmrEF or HFpEF. Methods and results: Heart failure patients with either HFpEF or HFmrEF were included in the study. During their first visit to the HF unit, serum samples were obtained and stored for later assessment of GDF-15 and NT-proBNP concentrations. Patients were followed up by the HF unit. The main endpoint was all-cause mortality. A total of 311 patients, 90 (29%) HFmrEF and 221 (71%) HFpEF, were included. Mean age was 72 ± 13 years, and 136 (44%) were women. No differences were found in GDF-15 or NT-proBNP concentrations between both HF groups. During a median follow-up of 15 months (Q1-Q3: 9-30 months), 98 patients (32%) died, most (71%) of cardiovascular causes. Patients who died had higher median concentrations of GDF-15 (4085 vs. 2270 ng/L, P < 0.0001) and NT-proBNP (1984 vs. 1095 ng/L, P < 0.0001). A Cox multivariable model identified New York Heart Association Functional Class III (P = 0.04), systolic blood pressure (P = 0.01), left atrial diameter (P = 0.03), age >65 years (P < 0.0001), and GDF-15 concentrations (P = 0.01) but not NT-proBNP as independent predictors of all-cause mortality. The area under the curve was 0.797 for the basic model including NT-proBNP, and the area under the curve comparing the overall model was 0.819, P = 0.016 (DeLong's test). Integrated discrimination improvement index after the inclusion of GDF-15 in the model with the mortality risk factors was 0.033; that is, the ability to predict death increased by 3.3% (P = 0.004). Net reclassification improvement was 0.548 (P < 0.001); that is, the capacity to improve the classification of the event (mortality) was 54.8%. GDF-15 concentrations were divided in tertiles (<1625, 1625-4330, and >4330 ng/L), and survival curves were evaluated using the Kaplan-Meier technique. Patients in the highest tertile had the poorest 5 year survival, at 16%, whereas the lowest tertile had the best survival, of 78% (P < 0.001). Conclusions: Growth differentiation factor 15 was superior to NT-proBNP for assessing prognosis in patients with HFpEF and HFmrEF. GDF-15 emerges as a strong, independent biomarker for identifying HFmrEF and HFpEF patients with worse prognosis.
Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension

Nils Nickel,Tibor Kempf,Heike Tapken,Jörn Tongers,Florian Laenger,Ulrich Lehmann,Heiko Golpon,Karen Olsson,Martin R Wilkins,J Simon R Gibbs,Marius M Hoeper,Kai C Wollert

DOI: https://doi.org/10.1164/rccm.200802-235OC

2008-09-01

Abstract:Rationale: Growth-differentiation factor (GDF)-15 is a stress-responsive, transforming growth factor-beta-related cytokine. Circulating levels of GDF-15 provide independent prognostic information in patients with acute pulmonary embolism and chronic left-sided heart failure. Objectives: To assess the prognostic value of GDF-15 in idiopathic pulmonary arterial hypertension. Methods: GDF-15 levels were determined in 76 treatment-naive patients at the time of baseline right heart catheterization. Patients were monitored for a median (range) of 48 (0-101) months (first cohort). Twenty-two additional patients were studied at baseline and 3 to 6 months after initiation of therapy (second cohort). Measurements and main results: Fifty-five percent of the patients in the first cohort presented with GDF-15 levels above 1,200 ng/L, the previously defined upper reference limit. The risk of death or transplantation at 3 years was 15 and 44% in patients with GDF-15 levels below or above 1,200 ng/L, respectively (P = 0.006). Elevated levels of GDF-15 were associated with increased mean right atrial and pulmonary capillary wedge pressures, a lower mixed venous oxygen saturation (Sv(O(2))), and higher levels of uric acid and N-terminal pro-brain natriuretic peptide (NT-proBNP). After adjustment for hemodynamic and biochemical variables, GDF-15 remained an independent predictor of adverse outcomes (P = 0.002). GDF-15 provided prognostic information in clinically relevant patient subgroups, and added prognostic information to hemodynamic variables and NT-proBNP. Changes in GDF-15 over time in the second cohort were related to changes in NT-proBNP (P = 0.031) and inversely related to changes in Sv(O(2)) (P < 0.001). Conclusions: GDF-15 is a promising new biomarker in idiopathic pulmonary arterial hypertension.
Susceptibility to killing by bcg‐activated macrophages associated with ‘spontaneous’ neoplastic transformation in culture

R. Tucker,M. Meltzer,K. Sanford

DOI: https://doi.org/10.1002/ijc.2910270420

1981-04-15

International Journal of Cancer

Abstract:Non‐tumorigenic and ‘spontaneously’ transformed tumorigenic paired cell lines derived from mouse, rat, or hamster embryonic tissues were examined for their susceptibility to killing by mouse peritoneal macrophages activated in vivo by infection with Mycobacterium bovis, strain Bacillus Calmette‐Guérin (BCG). Susceptibility to killing was measured by the extent of clearing in a confluent layer of target cells overlying an area of adherent macrophages or by the release of 3H counts from target cells prelabelled with [3H]‐thymidine. Only tumorigenic lines showed complete clearing by activated macrophages; the reaction occurred regardless of species differences between macrophages and target cells. The degree of clearing increased with increasing ratio of macrophages to target cells. Normal macrophages from uninfected mice did not produce a clearing reaction. The macrophage reaction discriminated between non‐tumorigenic and tumorigenic cells with short tumor latent periods (<100 days) even when neoplastic and non‐neoplastic cells were derived in culture from the same cell. The more tumorigenic lines (i.e., shortest latent period) tended to be more susceptible to killing. Thus, cells spontaneously transformed in culture are more susceptible to killing by activated macrophages than are their non‐neoplastic counterparts. In two cloned lines the enhanced susceptibility to macrophage killing appeared to be a late manifestation of the neoplastic change.
Growth Differentiation Factor-15 is a Biomarker for All-cause Mortality but Less Evident for Cardiovascular Outcomes: A Prospective Study

Xue Bao,Yan Borne,Biao Xu,Marju Orho-Melander,Jan Nilsson,Olle Melander,Gunnar Engstrom

DOI: https://doi.org/10.1016/j.ahj.2020.12.020

IF: 5.099

2021-01-01

American Heart Journal

Abstract:Background Previous studies have proposed growth differentiation factor-15 (GDF-15) as a predictor of adverse cardiovascular outcomes and mortality. The present study aimed to determine if such associations remain after accounting for death as a competing risk, and if GDF-15 provides superior prediction performance than other biomarkers. Methods Plasma GDF-15 levels and cardiovascular risk factors were measured in individuals without cardiovascular diseases (n = 4,143, aged 57.4 +/- 5.96 years, 38.6 % men) from Malmo Diet and Cancer-Cardiovascular Cohort and were followed up for more than 20 years. Incidence of coronary events, ischemic stroke, cardiovascular mortality, and all-cause mortality was studied in relation to GDF-15 using Cox proportional hazards regression, with adjustment for potential confounders. Confounding from death as competing risk was carefully checked using the Fine and Gray subdistribution hazard model. Predictive capabilities were further evaluated using C-statistics, continuous net reclassification improvement, and integrated discrimination improvement. Results During follow-up, 424 coronary events, 327 ischemic stroke, 368 cardiovascular deaths, and 1,308 all-cause deaths occurred. After controlling for death from other causes as competing events, only all-cause mortality remained sig-nificantly related to GDF-15. The addition of GDF-15 significantly improved prediction for all-cause mortality in addition to the traditional risk factors, high-sensitive C-reactive protein and N-terminal prohormone of brain natriuretic peptide. Only N-terminal prohormone of brain natriuretic peptide improved prediction for CVD mortality. Conclusions GDF-15 is a robust biomarker for all-cause mortality but less reliable for coronary event, ischemic stroke or cardiovascular mortality. Competing risk from death is an important consideration when interpreting the results.
A Meta-Analysis of Growth Differentiation Factor-15 and Prognosis in Chronic Heart Failure

Jin-Wen Luo,Wen-Hui Duan,Lei Song,Yan-Qiao Yu,Da-Zhuo Shi

DOI: https://doi.org/10.3389/fcvm.2021.630818

IF: 3.6

2021-11-05

Frontiers in Cardiovascular Medicine

Abstract:Background: Previous studies had reported increased circulating concentrations of growth differentiation factor-15 (GDF-15) in chronic heart failure (CHF), suggesting the potential prognostic significance of GDF-15 in this setting. To verify the relationship between the circulating GDF-15 levels and prognosis of CHF patients, we conducted an updated evidence-based meta-analysis. Methods: A comprehensive literature retrieval of PubMed, EMBASE, and Cochrane library was performed to collect the qualified studies that analyzed the prognostic value of GDF-15 in CHF from the inception of these online databases to September 25, 2021. The hazard ratio (HR) calculated for logGDF-15 of all-cause death and the related 95% confidence interval (CI) in multivariate analysis were used to measure the effect size. Additionally, subgroup analyses stratified by characteristics of the study participants were conducted for incremental evidence of GDF-15 in CHF with different clinical status. Results: A total of ten eligible studies involving 6,244 CHF patients were finally taken into the quantitative analysis. Results in the random-effects model indicated that there was an increased risk of 6% in all-cause mortality with a per 1LnU increase in baseline GDF-15 concentration (HR: 1.06, 95% CI: 1.03–1.10, P < 0.001). In stratified analyses, the association of GDF-15 with risk of all-cause mortality was found among chronic ischemic HF patients (HR:1.75, 95%CI: 1.24–2.48, P = 0.002), while the association was not found among chronic nonischemic HF patients (HR:1.01, 95%CI: 1.00–1.02, P = 0.219). Conclusion: The elevated GDF-15 is associated with an increased risk of all-cause mortality in CHF, especially, among CHF patients with ischemic etiology. The circulating GDF-15 might be a prognostic indicator in CHF patients. Registration Number: https://www.crd.york.ac.uk/PROSPERO ; CRD42020210796.

cardiac & cardiovascular systems

Studies on congenital orotic aciduria: comparison of orotic acid metabolism in microorganisms.

Growth differentiation factor–15 predicts the prognoses of patients with acute coronary syndrome: a meta-analysis

Monochromatic light sources in testing image intensifier tubes

Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease

Growth Differentiation Factor 15: A Prognostic Marker in Patients with Acute Chest Pain without Acute Myocardial Infarction

Prognostic value of growth differentiation factor-15 3 months after an acute chest pain admission

Growth Differentiation Factor 15, Its 12-Month Relative Change, and Risk of Cardiovascular Events and Total Mortality in Patients with Stable Coronary Heart Disease: 10-Year Follow-up of the KAROLA Study

Growth differentiation factor-15 and 5-years cardiovascular risk in chest pain patients presenting to the emergency department: a multicenter cohort study

Association between growth differentiation factor-15 and adverse outcomes among patients with heart failure: A systematic literature review

[The role of growth differentiation factor-15 in assessing the prognosis of patients after uncomplicated myocardial infarction]

Growth differentiation factor-15 predicts all-cause death and major adverse cardiovascular events in patients with coronary heart disease: a prospective cohort study

MOBILE LEARNING USING SMS : A MOBILE BUSINESS APPLICATION

Growth differentiation factor-15 combined with N-terminal prohormone of brain natriuretic peptide increase 1-year prognosis prediction value for patients with acute heart failure: a prospective cohort study.

Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial

Prognostic value of growth differentiation factor-15 in patients with coronary artery disease: A meta-analysis and systematic review

[Correlation Between Levels of Serum Growth Differentiation Factor-15 and Acute Coronary Syndrome].

Growth differentiation factor 15 as mortality predictor in heart failure patients with non-reduced ejection fraction

Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension

Susceptibility to killing by bcg‐activated macrophages associated with ‘spontaneous’ neoplastic transformation in culture

Growth Differentiation Factor-15 is a Biomarker for All-cause Mortality but Less Evident for Cardiovascular Outcomes: A Prospective Study

A Meta-Analysis of Growth Differentiation Factor-15 and Prognosis in Chronic Heart Failure